

Attorney Docket No.: 10017.200-US

SECTOR  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al.

Serial No.: 09/784,554

Confirmation No: 5362

Group Art Unit: 1651

Filed: February 16, 2001

Examiner: To be assigned

For: Family 44 Xyloglucanases

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Notice to File Missing Parts (in duplicate)
2. Copy of Notice to File Missing Parts
3. Executed Combined Declaration and Power of Attorney
4. Amendment and Marked Up Version pursuant to 37 C.F.R. 1.21
5. Sequence Listing
6. Disk Containing Sequence Listing
7. Certified copy of Priority Application(s)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on July 2, 2001.

Julie Tabarovsky  
(name of person mailing paper)

J. Tabarovsky  
(signature of person mailing paper)



Attorney Docket No.: 10017.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schnorr et al.

Serial No.: 09/784,554

Confirmation No: 5362

Group Art Unit: 1651

Filed: February 16, 2001

Examiner: To be assigned

For: Family 44 Xyloglucanases

RESPONSE TO NOTICE TO FILE MISSING PARTS

Commissioner for Patents  
Washington, DC 20231

Sir:


In response to the Notice to File Missing Parts dated May 1, 2001 (a copy thereof is attached hereto), Applicants submit the Combined Declaration and Power of Attorney signed and dated by Applicants for the above-captioned application.

Applicants also enclose a certified copy of Danish application no. PA 2000 00291, priority of which is claimed under 35 U.S.C. 119.

Please charge the required fee, estimated to be \$130.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. Please credit any overpayment to Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: July 2, 2001

  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/784,554	02/16/2001	Kirk Schnorr	10017.200-US

CONFIRMATION NO. 5362

## FORMALITIES LETTER



\*OC000000006026764\*

Novozymes North America, Inc.  
Suite 6400  
405 Lexington Avenue  
New York, NY 10174-6401

Date Mailed: 05/01/2001

## NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

## Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.  
*A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.*
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

MAIL ROOM RECEIVED 05/01/2001 10:00 AM

U.S. PATENT AND TRADEMARK OFFICE

For questions regarding compliance to these requirements, please contact:



- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

---

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE